{
  "id": 6610922,
  "title": "RedHill (RDHL) Acquires Rebyota and Clenpiq Commercialization Rights for $12M Upfront. Can Sales Outpace Royalties?",
  "url": "https://urgent.news/2026/09/10/redhill-rdhl-acquires-rebyota-and-clenpiq-commercialization-rights",
  "topic": "finance",
  "section": "Finance & Markets",
  "published": "2026-09-10T16:06:30.000Z",
  "source": {
    "name": "Yahoo Finance",
    "slug": "yahoo-finance",
    "url": "https://finance.yahoo.com/healthcare/articles/redhill-rdhl-acquires-rebyota-clenpiq-160630625.html"
  },
  "original_language": "en",
  "account": "RedHill Biopharma Ltd. (NASDAQ:RDHL) has acquired the commercialization rights to two gastrointestinal products from Ferring Pharmaceuticals. The $12 million upfront payment comes from the proceeds of Talicia divestiture. In addition to the upfront, RedHill Biopharma will receive tiered royalties between 5% and 20% of net sales, as well as potential milestone-based payments. The agreement covers Rebyota and Clenpiq, with the latter having already generated $37.5 million in combined US net sales in 2025. The structure limits RedHill Biopharma's upfront spending while relying on royalties, inventory funding, and supplier performance for economics.",
  "summary": null,
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}